Literature DB >> 32456967

Do ovarian endometriomas affect ovarian response to ovarian stimulation for IVF/ICSI?

Iñaki González-Foruria1, Pedro Barri Soldevila2, Ignacio Rodríguez2, Jorge Rodríguez-Purata2, Clara Pardos2, Sandra García2, M Ángela Pascual2, Pedro N Barri2, Nikolaos P Polyzos2.   

Abstract

RESEARCH QUESTION: Does the presence of ovarian endometriomas affect ovarian response to ovarian stimulation after adjusting for age and ovarian reserve markers?
DESIGN: This retrospective cross-sectional study compared the ovarian response between patients with ovarian endometriomas and women with other infertility factors undergoing their first ovarian stimulation for IVF/intracytoplasmic sperm injection (ICSI). An age-specific nomogram model for the number of oocytes retrieved was built for both groups, and ovarian response was compared after adjusting for age, gonadotrophin dose, anti-Mullerian hormone (AMH) concentration and antral follicle count (AFC).
RESULTS: A total of 923 patients were included: 101 women with at least one ovarian endometrioma, and 822 patients with other infertility factors. Comparisons of the nomograms for the number of oocytes retrieved demonstrated that response was significantly lower for women with endometrioma when the results were adjusted for age the z-score for the number of oocytes retrieved (-0.49 ± 0.71 versus -0.20 ± 0.86; 95% confidence interval [CI] -0.47 to -0.12) and also after adjustment for the total dose of gonadotrophins and AMH values (z-score mean difference -0.338; 95% CI -0.54, -0.14). When the z-score was adjusted for gonadotrophin dose and AFC, the number of oocytes retrieved was comparable between the two groups (z-score mean difference -0.038; 95% CI -0.34 to 0.27).
CONCLUSIONS: Ovarian response after ovarian stimulation for IVF/ICSI in women with endometriomas is significantly lower than in controls after adjusting for age, gonadotrophin dose and AMH. Dose and protocol selection for ovarian stimulation in patients with endometrioma should be based on AFC rather than AMH, as the latter may be overestimated.
Copyright © 2020 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-Müllerian hormone; Antral follicle count; Endometriosis; Ovarian reserve; Ovarian sensitivity index; Ovarian stimulation

Mesh:

Year:  2020        PMID: 32456967     DOI: 10.1016/j.rbmo.2020.03.013

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  5 in total

1.  Factors Influencing the Live Birth Rate Following Fresh Embryo Transfer Cycles in Infertile Women After Endometrioma Cystectomy.

Authors:  Wei Liu; Tongye Sha; Yuzhen Huang; Zizhen Guo; Lei Yan; Jinlong Ma
Journal:  Front Med (Lausanne)       Date:  2021-02-25

2.  Ovarian Endometrioma Negatively Impacts Oocyte Quality and Quantity But Not Pregnancy Outcomes in Women Undergoing IVF/ICSI Treatment: A Retrospective Cohort Study.

Authors:  Yaoqiu Wu; Rong Yang; Jie Lan; Haiyan Lin; Xuedan Jiao; Qingxue Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-22       Impact factor: 5.555

3.  Molecular Signatures Correlated With Poor IVF Outcomes: Insights From the mRNA and lncRNA Expression of Endometriotic Granulosa Cells.

Authors:  Libing Shi; Xianjiang Wei; Bingbing Wu; Chunhui Yuan; Chao Li; Yongdong Dai; Jianmin Chen; Feng Zhou; Xiang Lin; Songying Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-28       Impact factor: 5.555

4.  Does current ovarian endometrioma increase the time for DOR patients to reach live birth in IVF?

Authors:  Yu Deng; Zhanhui Ou; Minna Yin; Zhiheng Chen; Shiling Chen; Ling Sun
Journal:  BMC Pregnancy Childbirth       Date:  2022-04-15       Impact factor: 3.105

5.  The impact of endometrioma on in vitro fertilisation/intra-cytoplasmic injection IVF/ICSI reproductive outcomes: a systematic review and meta-analysis.

Authors:  Sallwa M Alshehre; Brenda F Narice; Mark A Fenwick; Mostafa Metwally
Journal:  Arch Gynecol Obstet       Date:  2020-09-26       Impact factor: 2.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.